Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%

MT Newswires Live

2025/09/15

Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.

Shares of the firm were up nearly 7% in Monday morning trade.

The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.

Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.

The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2567194040"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567194040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567194040?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567194040","market":"fut","top_or_hot":-1,"title":"Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-15 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567194040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567194040","pubTimestamp":1757904230,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Uni-Bio Science Group  said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm  to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK0239":"医药制造","BK1161":"生物科技","00690":"联康生物科技集团"},"translate_title":"Uni-Bio Science与科兴生物制药合作，将博古泰在六个市场商业化；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":0.9,"00690":0.9},"content_text":"Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}